Pharmala Biotech Holdings Inc. (CSE:MDMA)
Canada · Delayed Price · Currency is CAD | Market Cap | 17.97M +3.5% |
| Revenue (ttm) | 889.57K +106.8% |
| Net Income | -1.63M |
| EPS | -0.02 |
| Shares Out | 108.89M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 354,989 |
| Average Volume | 210,205 |
| Open | 0.1650 |
| Previous Close | 0.1650 |
| Day's Range | 0.1550 - 0.1650 |
| 52-Week Range | 0.0850 - 0.1950 |
| Beta | 0.70 |
| RSI | 60.96 |
| Earnings Date | Jul 17, 2026 |
About Pharmala Biotech Holdings
Pharmala Biotech Holdings Inc., doing business as PharmAla, focuses on the developing, manufacturing, and commercializing of substituted methylenedioxy-phenethylamines (MDXX) active pharmaceutical ingredients. It also provides MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB); and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), as well as formulations of MDXX compounds. The company is headquartered in Vancouver, Canada. [Read more]
Financial Performance
In fiscal year 2025, Pharmala Biotech Holdings's revenue was 605,498, a decrease of -41.51% compared to the previous year's 1.04 million. Losses were -2.18 million, 164.1% more than in 2024.
Financial StatementsNews
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002 to Jupiter Neurosciences in a Transaction Valued at Over $100 Million USD
PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01
TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) (“PharmAla” or the “Company”), a leader in the research, development, and manufacturing of clinical-...
PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01
TORONTO, April 27, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) (“PharmAla” or the “Company”), a biotechnology company focused on the research, development, and ma...
PharmAla Issues Q2 Financial Statements and Grants Options
TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and man...
Pharmala Biotech Holdings Earnings release: Q2 2026
Pharmala Biotech Holdings released its Q2 2026 earnings on April 21, 2026, summarizing the period's financial results.
Pharmala Biotech Holdings Registration statement: Q2 2026
Pharmala Biotech Holdings filed a registration statement on April 21, 2026, providing details about a securities offering with the SEC.
Pharmala Biotech Holdings Registration statement: Q2 2026
Pharmala Biotech Holdings filed a registration statement on April 21, 2026, providing details about a securities offering with the SEC.
PharmAla positioned to supply U.S. expanded access pathway for MDMA
PharmAla (MDXXF) Biotech responded to the Executive Order signed on April 18, 2026 by the President of the United States, which directs the U.S. Food and Drug Administration and the…
PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order
PharmAla is positioned to supply the US market with MDMA, and is advancing its next-generation patented safer MDMA product for human dosing this year.
Cortexa Advances Commercialisation of MDMA Supply in Australia
MELBOURNE, Australia, March 23, 2026 (GLOBE NEWSWIRE) -- Cortexa (Cortexa or the Company), a leading psychedelic medicines supplier, reaffirms its market leading position in FY2026 for MDMA (3,4-methy...
PharmAla signs supply, data agreement with Nautilus Sanctuary
PharmAla (MDXXF) Biotech executed a Supply & Data Agreement with Nautilus Sanctuary of Brooklyn, New York, for the provision of MDMA for use in a Phase 2 clinical trial in…
PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders
TORONTO, March 03, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and...
PharmAla signs drug donation agreement with Spaulding Rehabilitation
PharmAla (MDXXF) Biotech executed an agreement with Spaulding Rehabilitation for the provision of MDMA for use in a clinical trial investigating MDMA-assisted therapy for the treatment of fibromyalgia...
PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia
TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and ...
PharmAla to supply Amsterdam UMC with LaNeo MDMA
PharmAla (MDXXF) Biotech executed a binding supply agreement with Amsterdam University Medical Center in the Netherlands for the provision of LaNeo 40mg MDMA capsules for use in a proposed clinical…
PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data
TORONTO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and ...
PharmAla Announces Changes to Board of Directors
TORONTO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development, and man...
PharmAla to supply Ostfold Hospital Trust with LaNeo MDMA
PharmAla (MDXXF) Biotech has executed an agreement with Ostfold Hospital Trust of Norway. The sales agreement contains both financial and data-sharing provisions. PharmAla will seek to ship its LaNeo ...
PharmAla To Supply Østfold Hospital Trust with LaNeo™ MDMA for Clinical Research
TORONTO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development, and man...
PharmAla reports FY25 customer deposits C$276,000 vs. C$209,000 last year
PharmAla (MDXXF) Biotech Holdings has publicly filed its financial results for the periods ended August 31, 2025 and November 30th, respectively. “Commencing in late 2025 and continuing into Q1 2026…
PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements
TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manu...
Pharmala Biotech Holdings Registration statement: Q1 2026
Pharmala Biotech Holdings filed a registration statement on December 23, 2025, providing details about a securities offering with the SEC.
Pharmala Biotech Holdings Registration statement: Q1 2026
Pharmala Biotech Holdings filed a registration statement on December 23, 2025, providing details about a securities offering with the SEC.
Pharmala Biotech Holdings Earnings release: Q1 2026
Pharmala Biotech Holdings released its Q1 2026 earnings on December 23, 2025, summarizing the period's financial results.
Pharmala Biotech Holdings Earnings release: Q4 2025
Pharmala Biotech Holdings released its Q4 2025 earnings on December 23, 2025, summarizing the period's financial results.